‘Report Predicts World Revenues for Monoclonal Antibody Therapies Will Reach $62.3BN in 2015′ Says Visiongain

LONDON, September 20, 2011 -

www.visiongain.com/Report/685/Therapeutic-Monoclonal-Antibodies-World-Market-2011-2021

A new report by visiongain, a London-based business information company, predicts that overall revenues for monoclonal antibody (mAb) therapies will rise between 2011 and 2021. The world mAb drugs market will reach $62.3bn in 2015, up from revenues of $44.6bn (USD) in 2010. Those findings appear in Therapeutic Monoclonal Antibodies: World Market 2011-2021, published in September 2011.

Visiongain forecasts that the monoclonal antibody drug market will expand steadily to 2021. There will be sales growth in established and emerging markets, especially the US, Japan, China and India. The future of mAb technologies is promising, with high demand for novel treatments for cancer, autoimmune diseases and eye disorders in particular.

Diya Lahiri, pharmaceutical industry analyst, said: “The world market for monoclonal antibody treatments will benefit from the entry of new products this decade. There is much scope for therapies that offer improved administration methods, efficacy and tolerability, especially in the autoimmune disorders sector of the market.”

This new study predicts how treatments such as Avastin, Herceptin, MabThera, Remicade, Humira, Tysabri and Lucentis will perform to 2021. It shows commercial prospects for Roche, J&J, Abbott, Biogen Idec, Novartis and other companies. Markets and R&D pipelines for mAb-based treatments remain strong.

Products emerging from the R&D pipeline will help the monoclonal antibody treatments industry and market to grow this decade, the report explains. Also, the approval of existing products for new indications will expand the mAbs market and benefit patients. This new study adds to visiongain’s wide range of analytical reports in healthcare and other industry areas.

To see sample pages of the report please click on:

www.visiongain.com/Report/685/Therapeutic-Monoclonal-Antibodies-World-Market-2011-2021

Table of Contents

1. Executive Summary
1.1 Therapeutic Monoclonal Antibodies: World Market Outlook
1.2 Research and Analysis Methods
1.3 Chapter Outlines

2. Introduction to Monoclonal Antibodies
2.1 Antibodies
2.1.1 Function of Antibodies
2.1.2 Structure of Antibodies
2.2 Therapeutic Monoclonal Antibodies
2.2.1 Polyclonal and Monoclonal Antibodies
2.2.2 Murine Monoclonal Antibodies
2.2.3 Chimeric and Humanised Monoclonal Antibodies
2.2.4 Fully-Human Monoclonal Antibodies
2.2.5 Currently-Approved Monoclonal Antibody Therapies

3. World Therapeutic Monoclonal Antibodies Market, 2011-2021
3.1 Therapeutic Monoclonal Antibodies: Market Overview
3.1.1 The Therapeutic Monoclonal Antibody Market, 2010
3.1.2 Monoclonal Antibodies: Revenue Analysis by Therapeutic Area, 2010
3.1.3 Leading Therapeutic Monoclonal Antibodies, 2010
3.1.4 Leading Monoclonal Antibodies: Revenue Analysis by Group, 2010
3.1.5 World Monoclonal Antibody Market: Overall Forecast, 2010-2015
3.1.6 World Monoclonal Antibody Market: Overall Forecast, 2015-2021
3.2 The Market for Anti-Cancer Monoclonal Antibodies
3.2.1 The Leading Anti-Cancer Monoclonal Antibodies, 2010
3.2.2 Anti-Cancer Monoclonal Antibodies: Revenue Analysis by Type, 2010
3.2.3 Anti-Cancer Monoclonal Antibodies Market, 2010-2015
3.2.4 Anti-Cancer Monoclonal Antibodies Market, 2015-2021
3.3 The Monoclonal Antibodies for Treating Autoimmune Disorders Market
3.3.1 Leading Monoclonal Antibodies for Autoimmune Disorders: Revenue Analysis, 2010
3.3.2 Monoclonal Antibodies for Autoimmune Disorders: Types of Antibody Contributing to the Market
3.3.3 Remicade and Humira Drive the Autoimmune Disorders Treatment Market, 2010-2015
3.3.4 Monoclonal Antibodies for Autoimmune Disorders: Sales Forecast, 2015-2021
3.4 Monoclonal Antibodies for Other Therapeutic Uses
3.4.1 Other Leading Monoclonal Antibodies: Revenue Analysis, 2010
3.4.2 Other Monoclonal Antibodies: Sales Forecast, 2010-2021
3.5 Monoclonal Antibodies: Revenue Analysis by Company, 2010
3.6 Drivers and Restraints in the Market for Cancer and Autoimmune Disorders Monoclonal Antibodies

4. Leading Products in the Therapeutic Monoclonal Antibody Therapies Market, 2011-2021
4.1 Leading Anti-Cancer Monoclonal Antibodies in 2010
4.2 Avastin
4.2.1 Avastin: Cancer Blockbuster Set to Reach $10bn?
4.2.2 Avastin Revenue Analysis, 2010
4.2.3 Avastin 2010-2015: ‘Pipeline-in-One’
4.2.4 The Competitive Landscape for Avastin, 2010-2015
4.2.5 Avastin Revenue Forecast, 2010-2015
4.2.6 Avastin Revenue Forecast, 2015-2021
4.3 Herceptin
4.3.1 Herceptin for HER2-Positive Patients
4.3.2 Herceptin Revenue Analysis, 2010
4.3.3 Herceptin Revenue Forecast, 2010-2015
4.3.4 Increased Competition for Herceptin, 2015-2021
4.4 MabThera/Rituxan
4.4.1 MabThera/Rituxan: The First Blockbuster Monoclonal Antibody
4.4.2 MabThera/Rituxan Revenue Analysis, 2010
4.4.3 MabThera/Rituxan Revenue Forecast, 2010-2015
4.4.4 MabThera/Rituxan Revenue Forecast, 2015-2021
4.4.5 New Uses for MabThera/Rituxan Will Benefit Revenues
4.4.6 Intensifying Competition: MabThera/Rituxan in Cancer Treatment, 2015-2021
4.5 Erbitux
4.5.1 Erbitux’ Cancer Indications
4.5.2 Erbitux Revenue Analysis, 2010
4.5.3 Opportunities from New Indications for Erbitux
4.5.4 Erbitux Revenue Forecast, 2010-2021
4.6 Other Monoclonal Antibodies for Treating Cancers
4.6.1 Vectibix
4.6.2 Campath/MabCampath
4.6.3 Zevalin
4.6.4 Bexxar
4.6.5 TheraCIM (Nimotuzumab)
4.6.6 Removab
4.7 Leading Monoclonal Antibodies for Autoimmune Disorders in 2010
4.8 Remicade
4.8.1 Remicade: Leading Monoclonal Antibody, 2010
4.8.2 Remicade Revenue Analysis, 2010
4.8.3 Remicade’s Competitors
4.8.4 Imminent Increase in Competition for Remicade
4.8.5 Remicade Revenue Forecast, 2011-2015
4.8.6 Remicade Revenue Forecast, 2015-2021
4.9 Humira
4.9.1 Humira: First Fully-Human Monoclonal Antibody on the Market
4.9.2 Humira Revenue Analysis, 2010
4.9.3 Humira’s Market Potential, 2011-2015
4.9.4 Humira Revenue Forecast, 2015-2021
4.10 Tysabri
4.10.1 Tysabri - Monoclonal Antibody for the Treatment of MS
4.10.2 Tysabri Revenue Analysis, 2010
4.10.3 Tysabri Revenue Forecast, 2010-2021
4.10.4 Tysabri Will Face Competition from Oral MS Drugs
4.11 Xolair
4.11.1 Genentech’s Asthma Monoclonal Antibody
4.11.2 Xolair Revenue Analysis, 2010
4.11.3 Xolair Revenue Forecast, 2011-2021
4.12 MabThera/Rituxan
4.12.1 MabThera for Rheumatoid Arthritis
4.12.2 Competitors for MabThera/Rituxan in Autoimmune Disorders, 2011-2015
4.12.3 Prospects for Revenue Growth
4.13 Actemra
4.13.1 Actemra for Rheumatoid Arthritis
4.13.2 Actemra Revenue Forecast, 2011-2021
4.14 Cimzia
4.14.1 Cimzia for Crohn’s Disease
4.14.2 Cimzia Revenue Forecast, 2011-2021
4.15 Other Monoclonal Antibodies for Autoimmune Diseases
4.15.1 Simponi
4.15.2 Soliris
4.15.3 Simulect
4.15.4 Stelara
4.16 Other Monoclonal Antibodies
4.16.1 Other Leading Monoclonal Antibodies: Revenue Analysis, 2010
4.17 Synagis
4.17.1 Synagis: Blockbuster Respiratory Disorder Treatment
4.17.2 Synagis Revenue Analysis, 2010
4.17.3 Synagis Revenue Forecast, 2011-2021
4.18 Lucentis
4.18.1 Lucentis: Important Ophthalmological Drug
4.18.2 Lucentis Revenue Analysis, 2010
4.18.3 Impact of Off-Label Avastin on Lucentis, 2010-2021
4.18.4 Lucentis Revenue Forecast, 2011-2015
4.18.5 Lucentis Revenue Forecast, 2015-2021
4.19 ReoPro
4.19.1 ReoPro: Cardiovascular Monoclonal Antibody Fragment

5. Leading National Markets for Monoclonal Antibody Therapies, 2011-2021
5.1 Overview of Leading National Markets
5.1.1 Top Nine National Markets for Therapeutic Monoclonal Antibodies
5.2 The US Monoclonal Antibody Therapies Market, 2010-2021
5.2.1 US Market in 2010
5.2.2 US Monoclonal Antibody Therapies Market, 2011-2021
5.3 Japanese Monoclonal Antibody Therapies Market, 2010-2021
5.4 Leading European Monoclonal Antibody Therapies Markets, 2010-2021
5.5 Prospects for Therapeutic Monoclonal Antibody Sales in China and India, 2010-2021

6. R&D Pipeline for Therapeutic Monoclonal Antibodies, 2011
6.1 Late-Stage Oncology Pipeline: Additional and Expanded Indications
6.1.1 Avastin
6.1.2 MabThera/Rituxan
6.1.3 Erbitux
6.1.4 Tysabri
6.2 Late-Stage Oncology Pipeline: Novel Entities
6.2.1 Farletuzumab (MORAb-003)
6.2.2 Figitumumab (CP-751871)
6.2.3 Galiximab
6.2.4 Ipilimumab
6.2.5 Ramucirumab (IMC 1121B)
6.2.6 Rencarex (WX-G250)
6.2.7 Zalutumumab (HuMax-EGFr)
6.2.8 Lumiliximab
6.2.9 Pertuzumab (R1273)
6.3 Late-Stage Autoimmune Disorders Pipeline: Additional and Expanded Indications
6.3.1 MabThera/Rituximab
6.3.2 Alemtuzumab for Multiple Sclerosis
6.4 Late-Stage Autoimmune Disorders Pipeline: New Entities
6.4.1 Benlysta (Belimumab)
6.4.2 Bapineuzumab (AAB-001)
6.4.3 Briakinumab (ABT-874)
6.4.4 Mycograb (Efungumab)
6.4.5 Ocrelizumab (R1594)
6.4.6 Otelixizumab (TRX4)
6.5 Pipeline for Other Monoclonal Antibodies
6.5.1 Motavizumab
6.5.2 Lucentis
6.6 R&D Pipeline: Antibody Fragments
6.6.1 Development and Potential of Antibody Fragments
6.6.2 Ablynx’ Nanobodies
6.6.3 Domantis’ Domain Fragments
6.6.4 Genmab’s UniBody
6.6.5 ESBATech
6.6.6 Affimed’s TandAbs and Flexibodies
6.6.7 Micromet’s BiTE Antibody Platform
6.7 R&D Pipeline: Antibody-Drug Conjugates
6.7.1 The Future of Conjugated Antibodies
6.7.2 Seattle Therapeutics
6.7.3 ImmunoGen
6.7.4 Neuradiab

7. Drivers and Restraints in the Therapeutic Monoclonal Antibody Industry and Market, 2011-2021
7.1 SWOT Analysis of the Therapeutic Monoclonal Antibody Industry and Market, 2011-2021
7.2 Commercial Strengths
7.2.1 Monoclonal Antibodies Have a Wide Range of Specific Targets
7.2.2 Chronic and Niche Diseases Can Generate High Revenues
7.2.3 Strong R&D Pipeline and Technological Advances, Including Manufacturing Improvements
7.2.4 Lower Risk of Adverse Events for Monoclonal Antibodies in Cancer Treatment
7.3 Commercial Weaknesses
7.3.1 Biosimilars/Follow-on Biologics - Threat to Original-Branded Antibodies?
7.3.2 Future Prospects for Biosimilar Monoclonal Antibodies
7.3.3 High Development Cost Limits Growth
7.3.4 Injections are the Main Mode of Administration
7.3.5 The Challenge of Immunogenicity
7.3.6 Competition is Fierce for Many Targets
7.3.7 Insufficient Efficacy of Anti-Cancer Monoclonal Antibodies as Monotherapy is a Concern
7.4 Commercial Opportunities
7.4.1 Increasing Cancer Prevalence - Expanding Treatment Populations
7.4.2 Autoimmune Disorder Prevalence and Under-Treatment
7.5 Commercial Threats
7.5.1 Reimbursement for Monoclonal Antibodies
7.5.2 High Profile Safety Cases Increase Regulatory Vigilance
7.5.3 Current Financial Limitations in Research and Development

8. Research Interviews
8.1 Dr David Blakey, Chief Scientist, Cancer & Infection Research Area, AstraZeneca
8.1.1 The Future of Humanised and Fully-Human Antibodies
8.1.2 Therapeutic Antibody Fragments vs Full-Length Antibodies
8.1.3 Opportunities in Monoclonal Antibody Cancer Therapeutics
8.2 Dr Mark Cragg, Cancer Sciences Division, Southampton General Hospital, Southampton, UK
8.2.1 How Do Monoclonal Antibodies Treat Cancer?
8.2.2 The Future of Different Monoclonal Antibody Types
8.2.3 Threats and Limitations
8.2.4 Opportunities
8.2.5 Will Side Effects Limit Potential?
8.2.6 Future Developments
8.3 Dr Janice Reichert, Tufts Center for the Study of Drug Development, and Editor-in-Chief, mAbs
8.3.1 On the Reasons for the Ascendancy of MAbs
8.3.2 On the Current Indications for MAbs
8.3.3 On Antibody-Drug Conjugates and Biospecifics
8.3.4 On Non-Human Antibodies and Alternative Scaffolds
8.3.5 On the Prospects for Biosimilar Antibodies

9. Conclusions
9.1 Monoclonal Antibodies Are Important Contributors to Biologic Drug Revenues
9.2 Prospects for the Therapeutic Monoclonal Antibody Industry and Market
9.3 The Monoclonal Antibody R&D Pipeline
9.4 Monoclonal Antibodies Therapies Market from 2010 to 2015
9.5 Monoclonal Antibodies Therapies Market from 2015 to 2021
9.6 Expansion into New Markets
9.7 Concluding Thoughts

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Telecoms, Energy, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

For an exec summary please email Sara Peerun on:
Email: sara.peerun@visiongainglobal.com
Tel: +4402073366100
Web: www.visiongain.com

.